




Instance: composition-en-f9f99ae69c31ce78eb86e2425f62e81a
InstanceOf: CompositionUvEpi
Title: "Composition for tybost Package Leaflet"
Description:  "Composition for tybost Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp41eee0aef9958de83574342bcb523a83)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - tybost"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Tybost is and what it is used for </li>
<li>What you need to know before you take Tybost </li>
<li>How to take Tybost </li>
<li>Possible side effects </li>
<li>How to store Tybost </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What tybost is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What tybost is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tybost contains the active substance cobicistat. </p>
<p>Tybost is used for the treatment of human immunodeficiency virus-1 (HIV-1) infection, the virus that 
causes acquired immune deficiency syndrome (AIDS).  It is used in HIV-1 infected adults and 
adolescents aged 12 years and older: 
* weighing at least 35 kg (when co-administered with atazanavir 300 mg) or 
* weighing at least 40 kg (when co-administered with darunavir 800 mg). </p>
<p>Tybost acts as a booster (enhancer) of atazanavir or darunavir (both protease inhibitors) to improve 
their effect (see section 3 of this leaflet). </p>
<p>Tybost does not directly treat your HIV, but boosts the levels of atazanavir and darunavir in the 
blood.  It does this by slowing down the breakdown of atazanavir and darunavir which will make them 
stay in the body for longer. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take tybost"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take tybost"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Tybost </p>
<ul>
<li>
<p>If you are allergic to cobicistat or any of the other ingredients of this medicine (listed in 
section 6 of this leaflet). </p>
</li>
<li>
<p>If you are taking medicines containing any of the following:</p>
</li>
<li>
<p>alfuzosin, used to treat an enlarged prostate gland </p>
</li>
<li>amiodarone, quinidine, used to correct irregular heartbeats </li>
<li>dabigatran, used to prevent and treat blood clots </li>
<li>carbamazepine, phenobarbital, phenytoin, used to prevent seizures </li>
<li>rifampicin, used to prevent and treat tuberculosis and other infections </li>
<li>dihydroergotamine, ergometrine, ergotamine, used to treat migraine headache </li>
<li>St. John s wort (Hypericum perforatum), a herbal remedy used for depression and 
anxiety </li>
<li>lovastatin, simvastatin, used to lower blood cholesterol </li>
<li>pimozide, lurasidone, used to treat abnormal thoughts or feelings </li>
<li>sildenafil, used to treat pulmonary arterial hypertension   a lung disease that makes 
breathing difficult </li>
<li>orally administered midazolam, triazolam, used to help you sleep and/or relieve anxiety </li>
</ul>
<p>If any of these applies to you, you should not take Tybost and you should tell your doctor 
immediately. </p>
<p>Warnings and precautions </p>
<p>You must remain under the care of your doctor while taking Tybost. </p>
<p>Talk to your doctor before taking Tybost: </p>
<ul>
<li>
<p>If you are taking another protease inhibitor.  Tybost taken with atazanavir or darunavir 
should not be used with another antiviral medicine that requires boosting. </p>
</li>
<li>
<p>Talk to your doctor or pharmacist if you have or have had kidney disease, or if tests have 
shown problems with your kidneys.  Your doctor will carefully consider whether to treat you 
with Tybost. </p>
</li>
<li>
<p>Talk to your doctor or pharmacist if you have or have had severe liver disease, or if tests 
have shown problems with your liver.  Your doctor will carefully consider whether to treat 
you with Tybost. </p>
</li>
</ul>
<p>If any of these applies to you, talk to your doctor before taking Tybost. </p>
<p>Children and adolescents </p>
<p>Do not give this medicine to children under 12 years of age, or who weigh less than 35 kg (or 40 kg) 
as explained in section 3 of this leaflet.  The use of Tybost in children under 12 years of age or who 
weigh less than 35 kg has not yet been studied. </p>
<p>Other medicines and Tybost </p>
<p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines.  Tybost may interact with other substances.  As a result, the amounts of Tybost or other 
medicines in your blood may be affected.  This may stop your medicines from working properly, or 
may make any side effects worse.  In some cases, your doctor may need to adjust your dose or check 
the levels of medicine in your blood. </p>
<p>There are some medicines that should never be taken with Tybost. 
These are mentioned above under the heading  Do not take Tybost-If you are taking medicines 
containing any one of the following . </p>
<p>Medicines used in treating HIV infection: 
You should not take Tybost with other medicines containing: 
* ritonavir 
* cobicistat 
Talk to your doctor if you are taking 
* another protease inhibitor 
* efavirenz 
* etravirine 
* nevirapine 
* maraviroc 
  Tell your doctor if you are taking any of these HIV medicines. </p>
<p>Other types of medicine: 
* ketoconazole, itraconazole, voriconazole, posaconazole and fluconazole, medicines used to 
treat fungal infections 
* clarithromycin and rifabutin, medicines used to treat bacterial infections including 
tuberculosis 
* dasatinib, nilotinib, vinblastine and vincristine, medicines used to treat cancer 
* corticosteroids including betamethasone, budesonide, fluticasone, mometasone, 
prednisone, triamcinolone.  These medicines are used to treat allergies, asthma, inflammatory 
bowel diseases, inflammatory conditions of the skin, eyes, joints and muscles and other 
inflammatory conditions.  These medicines are generally taken orally, inhaled, injected or 
applied to the skin or eye.  If alternatives cannot be used, its use should only take place after 
medical evaluation and under close monitoring by your doctor for corticosteroid side effects. 
* metformin, medicine used for the treatment of type 2 diabetes 
* oral or implanted hormonal contraceptives used to prevent pregnancy 
* amlodipine, digoxin, diltiazem, disopyramide, felodipine, flecainide, lidocaine, metoprolol, 
mexiletine, nicardipine, nifedipine, propafenone, timolol and verapamil, medicines used to 
treat heart problems 
* bosentan, a medicine used to treat pulmonary arterial hypertension 
* apixaban, edoxaban, rivaroxaban and warfarin, medicines used to prevent and treat blood 
clots 
* salmeterol, a medicine used to treat asthma 
* atorvastatin, fluvastatin, pitavastatin, pravastatin and rosuvastatin, medicines used to lower 
cholesterol 
* sildenafil and vardenafil, medicines used to treat impotence, and tadalafil, a medicine used to 
treat impotence and pulmonary hypertension 
* trazodone, a medicine used to treat depression 
* ciclosporin, sirolimus and tacrolimus, medicines used to control your body s immune 
response after a transplant 
* buspirone, clorazepate, diazepam, estazolam, flurazepam, perphenazine, risperidone, 
thioridazine, zolpidem, medicines used to treat nervous system disorders 
* colchicine, a medicine used to treat gout 
* clopidogrel, a medicine used to reduce the risk of blood clots </p>
<p>Tell your doctor if you are taking any of these medicines. </p>
<p>Tell your doctor if you are taking these or any other medicines.  Do not stop your treatment 
without contacting your doctor. </p>
<p>Pregnancy and breast-feeding </p>
<p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine. </p>
<ul>
<li>
<p>Tell your doctor immediately if you are pregnant, think you may be pregnant or are 
planning to have a baby.  Pregnant women should not take Tybost with atazanavir or 
darunavir.  The amounts of these medicines in your blood may decrease during pregnancy, 
which may stop them from working properly.   </p>
</li>
<li>
<p>Do not breast-feed during treatment with Tybost.  It is not known if the active substance in 
this medicine can pass into human breast milk. </p>
</li>
<li>
<p>Breast-feeding is not recommended in women living with HIV because HIV infection can be 
passed on to the baby in breast milk. </p>
</li>
<li>If you are breast-feeding, or thinking about breast-feeding, you should discuss it with your 
doctor as soon as possible. </li>
</ul>
<p>Driving and using machines </p>
<p>Some patients have reported dizziness when Tybost was taken with atazanavir or darunavir.  If you are 
affected while taking Tybost, do not drive and do not use any tools or machines. </p>
<p>Tybost contains sunset yellow FCF (E110) </p>
<p>Tell your doctor if you have an allergy to sunset yellow FCF (E110).  Tybost contains sunset 
yellow FCF which may cause allergic reactions. </p>
<p>Tybost contains sodium </p>
<p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 
 sodium-free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take tybost"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take tybost"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you.  Check with your doctor or pharmacist 
if you are not sure. </p>
<p>Recommended dose for adults: </p>
<ul>
<li>One tablet each day by mouth, with food.  Do not chew, crush or split the tablet. </li>
<li>Tybost must be taken with atazanavir (300 mg) or darunavir (800 mg). </li>
</ul>
<p>Recommended dose for adolescents 12 to less than 18 years of age: </p>
<ul>
<li>One tablet each day by mouth, with food.  Do not chew, crush or split the tablet. </li>
<li>When taking Tybost with atazanavir (300 mg), adolescents must weigh at least 35 kg. </li>
<li>When taking Tybost with darunavir (800 mg), adolescents must weigh at least 40 kg. </li>
</ul>
<p>Always take the dose recommended by your doctor.  This is to make sure that your medicine is 
fully effective.  Do not change the dose unless your doctor tells you to. </p>
<p>If you take more Tybost than you should </p>
<p>If you accidentally take more than the recommended dose of Tybost you may be at increased risk of 
experiencing side effects with this medicine (see section 4 of this leaflet). </p>
<p>Contact your doctor or nearest emergency department immediately for advice.  Keep the tablet bottle 
with you so that you can easily describe what you have taken. </p>
<p>If you forget to take Tybost </p>
<p>It is important not to miss a dose of Tybost. </p>
<p>If you do miss a dose and notice: </p>
<ul>
<li>
<p>within 12 hours of the time you usually take Tybost, you must take the tablet as soon as 
possible.  Always take the tablet with food.  Then take the next dose as usual in combination 
with atazanavir or darunavir. </p>
</li>
<li>
<p>12 hours or more after the time you usually take Tybost, then do not take the missed dose.<br />
Wait and take the next dose, with food, at your usual time. </p>
</li>
</ul>
<p>Do not stop taking Tybost </p>
<p>Do not stop taking Tybost without talking to your doctor.  Stopping Tybost and atazanavir or 
darunavir may reduce the success of future treatments prescribed by your doctor. </p>
<p>Always keep enough Tybost so you don t run out.  When your supply of Tybost starts to run low, 
get more from your doctor or pharmacist. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.  When 
treating HIV infection, it is not always possible to tell whether some of the unwanted effects are 
caused by Tybost or by other medicines that you are taking at the same time, or by the HIV disease 
itself.  The following side effects may occur when taking Tybost with atazanavir. </p>
<p>Very common side effects 
(may affect more than 1 in 10 people) 
* feeling sick (nausea) 
* yellowing of the skin and/or eyes (jaundice) 
Common side effects 
(may affect up to 1 in 10 people) 
* high sugar levels in the blood (hyperglycaemia) 
* increased appetite, disturbed sense of taste, dry mouth 
* headache, dizziness 
* vomiting, diarrhoea, stomach pain, problems with digestion resulting in pain after meals 
(dyspepsia), feeling bloated, wind (flatulence) 
* increased levels of bilirubin in the blood (hyperbilirubinaemia) 
* rash 
* difficulty sleeping, abnormal dreams, drowsiness, tiredness (fatigue) 
Uncommon side effects 
(may affect up to 1 in 100 people) 
* blood in the urine (haematuria) 
* protein in the urine (proteinuria) 
* feeling depressed 
* itchiness 
* aching muscles, weakness 
* kidney stones 
* fever 
* sleep disorder </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist.  This includes any possible side 
effects not listed in this leaflet.  You can also report side effects directly via the national reporting 
system listed in Appendix V.  By reporting side effects you can help provide more information on the 
safety of this medicine. </p>
<p>For more information on the side effects of atazanavir or darunavir see the package leaflets for these 
medicines. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store tybost"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store tybost"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the bottle and carton after {EXP}.<br />
The expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special storage conditions. </p>
<p>Do not throw away any medicines via wastewater or household waste.  Ask your pharmacist how to 
throw away medicines you no longer use.  These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Tybost contains </p>
<p>The active substance is cobicistat.  Each film-coated tablet contains 150 mg cobicistat. </p>
<p>The other ingredients are </p>
<p>Tablet core 
Croscarmellose sodium, magnesium stearate, microcrystalline cellulose (E460), silicon dioxide 
(E551). </p>
<p>Film-coating 
Sunset yellow FCF (E110), macrogol 3350 (E1521), polyvinyl alcohol (partially hydrolysed) (E1203), 
talc (E553b), titanium dioxide (E171), iron oxide yellow (E172) (see section 2 of this leaflet). </p>
<p>What Tybost looks like and contents of the pack </p>
<p>Tybost film-coated tablets are orange, round, biconvex tablets, debossed on one side with  GSI  and 
plain-faced on the other side of the tablet. </p>
<p>Tybost comes in bottles of 30 tablets (with a silica gel sachet or canister that must be kept in the bottle 
to help protect your tablets).  The silica gel desiccant is contained in a separate sachet or canister and 
should not be swallowed. </p>
<p>The following pack sizes are available: outer cartons containing 1 bottle of 30 film-coated tablets and 
90 (3 bottles of 30) film-coated tablets.  Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder 
Gilead Sciences Ireland UC 
Carrigtohill 
County Cork, T45 DPIreland </p>
<p>Manufacturer 
Gilead Sciences Ireland UC 
IDA Business &amp; Technology Park 
Carrigtohill 
County Cork 
Ireland </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Gilead Sciences Belgium SRL-BV 
T l/Tel: + 32 (0) 24 01 35 Lietuva 
Gilead Sciences Ireland UC 
Tel: + 353 (0) 1 686 1<br />
Gilead Sciences Ireland UC 
 .: + 353 (0) 1 686 1Luxembourg/Luxemburg 
Gilead Sciences Belgium SPRL-BVBA 
T l/Tel: + 32 (0) 24 01 35  esk  republika 
Gilead Sciences s.r.o. 
Tel: + 420 910 871 Magyarorsz g 
Gilead Sciences Ireland UC 
Tel.: + 353 (0) 1 686 1Danmark 
Gilead Sciences Sweden AB 
Tlf: + 46 (0) 8 5057 1Malta 
Gilead Sciences Ireland UC 
Tel: + 353 (0) 1 686 1Deutschland 
Gilead Sciences GmbH 
Tel: + 49 (0) 89 899890-0 </p>
<p>Nederland 
Gilead Sciences Netherlands B.V. 
Tel: + 31 (0) 20 718 36 Eesti 
Gilead Sciences Ireland UC 
Tel: + 353 (0) 1 686 1Norge 
Gilead Sciences Sweden AB 
Tlf: + 46 (0) 8 5057 1<br />
Gilead Sciences    . . 
 : + 30 210 8930  sterreich 
Gilead Sciences GesmbH 
Tel: + 43 1 260 Espa a 
Gilead Sciences, S.L. 
Tel: + 34 91 378 98 Polska 
Gilead Sciences Poland Sp. z o.o. 
Tel.: + 48 22 262 8France 
Gilead Sciences 
T l: + 33 (0) 1 46 09 41 Portugal 
Gilead Sciences, Lda. 
Tel: + 351 21 7928Hrvatska 
Gilead Sciences Ireland UC 
Tel: + 353 (0) 1 686 1Rom nia 
Gilead Sciences (GSR) S.R.L. 
Tel: + 40 31 631 18 Ireland 
Gilead Sciences Ireland UC 
Tel: + 353 (0) 214 825 Slovenija 
Gilead Sciences Ireland UC 
Tel: + 353 (0) 1 686 1 sland 
Gilead Sciences Sweden AB 
S mi: + 46 (0) 8 5057 1Slovensk  republika 
Gilead Sciences Slovakia s.r.o. 
Tel: + 421 232 121 Italia 
Gilead Sciences S.r.l. 
Tel: + 39 02 439Suomi/Finland 
Gilead Sciences Sweden AB 
Puh/Tel: + 46 (0) 8 5057 1<br />
Gilead Sciences    . . 
 : + 30 210 8930 Sverige 
Gilead Sciences Sweden AB 
Tel: + 46 (0) 8 5057 1Latvija 
Gilead Sciences Ireland UC 
Tel: + 353 (0) 1 686 1United Kingdom (Northern Ireland) 
Gilead Sciences Ireland UC 
Tel: + 44 (0) 8000 113 This leaflet was last revised in {MM/YYYY}. </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-f9f99ae69c31ce78eb86e2425f62e81a
InstanceOf: CompositionUvEpi
Title: "Composition for tybost Package Leaflet"
Description:  "Composition for tybost Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp41eee0aef9958de83574342bcb523a83)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - tybost"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal De vide, før De begynder at tage Tybost </li>
<li>Sådan skal De tage Tybost </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What tybost is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What tybost is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tybost indeholder det aktive stof cobicistat. </p>
<p>Tybost anvendes til behandling af human immundefektvirus-1 (hiv-1) infektion – det virus, der giver 
erhvervet immundefektsyndrom (aids). Det anvendes hos hiv-1 inficerede voksne og unge i alderen 
12 år og derover:  </p>
<ul>
<li>
<p>som vejer mindst 35 kg (når det gives sammen med atazanavir 300 mg) eller </p>
</li>
<li>
<p>som vejer mindst 40 kg (når det gives sammen med darunavir 800 mg) </p>
</li>
</ul>
<p>Tybost virker som en booster (forstærkende middel) til atazanavir eller darunavir (begge 
proteasehæmmere) for at hjælpe med at forbedre deres virkning (se afsnit 3 i denne indlægsseddel). </p>
<p>Tybost behandler ikke Deres hiv direkte, men forhøjer niveauer af atazanavir og darunavir i 
blodet. Tybost gør dette ved at sænke nedbrydningshastigheden af atazanavir og darunavir, hvilket vil 
få dem til at forblive i kroppen i længere tid. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take tybost"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take tybost"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Tybost </p>
<ul>
<li>
<p>Hvis De er allergisk over for cobicistat eller et af de øvrige indholdsstoffer i denne medicin 
(angivet i punkt 6 i denne indlægsseddel). </p>
</li>
<li>
<p>Hvis De tager lægemidler, der indeholder nogle af følgende:</p>
</li>
<li>
<p>alfuzosin, anvendes til at behandle en forstørret blærehalskirtel </p>
</li>
<li>dabigatran, anvendes til at forebygge og behandle blodpropper </li>
<li>amiodaron, quinidin, anvendes til at korrigere uregelmæssige hjerteslag </li>
<li>
<p>carbamazepin, phenobarbital, phenytoin, anvendes til at forebygge krampeanfald </p>
</li>
<li>
<p>rifampicin, anvendes til at forebygge og behandle tuberkulose og andre infektioner </p>
</li>
<li>dihydroergotamin, ergometrin, ergotamin, anvendes til at behandle migræne-
hovedpine </li>
<li>prikbladet perikum (Hypericum perforatum), et naturlægemiddel, der anvendes mod 
depression og angst </li>
<li>lovastatin, simvastatin, anvendes til at sænke kolesterol i blodet </li>
<li>pimozid, lurasidon, anvendes til at behandle unormale tanker og følelser </li>
<li>sildenafil, anvendes til at behandle pulmonal arteriel hypertension – en lungesygdom, der 
gør det vanskeligt at trække vejret </li>
<li>oralt administreret midazolam, triazolam, anvendes til at hjælpe dig med at sove og/eller 
lindre angst </li>
</ul>
<p> Hvis noget af dette gælder for Dem, må De ikke tage Tybost og De skal omgående fortælle 
Deres læge det. </p>
<p>Advarsler og forsigtighedsregler </p>
<p>De skal fortsætte med at være under lægens opsyn, mens De tager Tybost. </p>
<p>Kontakt lægen, før De tager Tybost: </p>
<ul>
<li>
<p>Hvis De tager en anden proteasehæmmer. Tybost taget med atazanavir eller darunavir må 
ikke anvendes sammen med andre antivirale lægemidler, der kræver forstærkning. </p>
</li>
<li>
<p>Tal med lægen eller apotekspersonalet, hvis De har eller har haft nyresygdom, eller hvis 
prøver har vist problemer med Deres nyrer. Deres læge vil nøje overveje, om De skal 
behandles med Tybost. </p>
</li>
<li>
<p>Tal med lægen eller apotekspersonalet, hvis De har eller har haft svær leversygdom, eller 
hvis prøver har vist problemer med Deres lever. Deres læge vil nøje overveje, om De skal 
behandles med Tybost. </p>
</li>
</ul>
<p> Hvis noget af dette gælder for Dem, skal De tale med lægen før De tager Tybost. </p>
<p>Børn og unge </p>
<p>Denne medicin må ikke gives til børn under 12 år eller som vejer mindre end 35 kg (eller 40 kg) som 
forklaret i afsnit 3 i denne indlægsseddel. Anvendelsen af Tybost til børn under 12 år, eller som vejer 
under 35 kg er ikke undersøgt endnu. </p>
<p>Brug af andre lægemidler sammen med Tybost </p>
<p>Fortæl altid lægen eller apotekspersonalet, hvis De tager andre lægemidler, for nylig har taget 
andre lægemidler eller planlægger at tage andre lægemidler. Tybost kan påvirke andre stoffer. 
Som et resultat heraf kan mængden af Tybost eller anden medicin i Deres blod påvirkes. Dette kan 
forhindre, at Deres medicin virker korrekt, eller det kan gøre bivirkninger værre. I nogle tilfælde kan 
det være nødvendigt, at lægen justerer Deres dosis eller kontrollerer niveauet af medicin i Deres blod. </p>
<p>Visse lægemidler må aldrig tages sammen med Tybost. 
De er nævnt ovenfor under overskriften “Tag ikke Tybost - Hvis De tager lægemidler, der indeholder 
nogle af følgende". </p>
<p>Lægemidler anvendt til behandling af hiv-infektion: 
De må ikke tage Tybost med andre lægemidler, der indeholder: </p>
<ul>
<li>
<p>ritonavir </p>
</li>
<li>
<p>cobicistat </p>
</li>
</ul>
<p>Tal med Deres læge, hvis De tager </p>
<ul>
<li>
<p>en anden proteasehæmmer </p>
</li>
<li>
<p>efavirenz </p>
</li>
<li>
<p>etravirin </p>
</li>
<li>
<p>nevirapin </p>
</li>
<li>
<p>maraviroc 
 
Fortæl lægen, hvis De tager en eller flere af disse hiv-lægemidler. </p>
</li>
</ul>
<p>Andre typer lægemidler: </p>
<ul>
<li>
<p>ketoconazol, itraconazol, voriconazol, posaconazol og fluconazol, lægemidler, der anvendes 
til at behandle svampeinfektioner </p>
</li>
<li>
<p>clarithromycin og rifabutin, lægemidler, der anvendes til at behandle bakterieinfektioner, 
herunder tuberkulose </p>
</li>
<li>
<p>dasatinib, nilotinib, vinblastin og vincristin, lægemidler, der anvendes til at behandle kræft </p>
</li>
<li>
<p>kortikosteroider, herunder betamethason, budesonid, fluticason, mometason, prednison og 
triamcinolon. Disse lægemidler anvendes til behandling af allergier, astma, inflammatoriske 
(betændelseslignende) tarmsygdomme, inflammatoriske tilstande i hud, øjne, led og muskler 
samt andre inflammatoriske tilstande. Disse lægemidler tages normalt gennem munden, 
inhaleres, injiceres eller påføres huden eller øjet. De må kun bruge disse lægemidler, hvis andre 
lægemidler ikke kan anvendes, og kun efter en lægelig vurdering og under tæt lægelig 
overvågning for kortikosteroid-bivirkninger </p>
</li>
<li>
<p>metformin, lægemiddel, der anvendes til at behandle type 2-diabetes </p>
</li>
<li>
<p>orale eller implanterede hormonale præventionsmidler, der anvendes til at forebygge 
graviditet </p>
</li>
<li>
<p>amlodipin, digoxin, diltiazem, disopyramid, felodipin, flecainid, systemisk lidocain, 
metoprolol, mexiletin, nicardipin, nifedipin, propafenon, timolol og verapamil, lægemidler, 
der anvendes til at behandle hjerteproblemer </p>
</li>
<li>
<p>bosentan, et lægemiddel, der anvendes til at behandle pulmonal arteriel hypertension </p>
</li>
<li>
<p>apixaban, edoxaban, rivaroxaban og warfarin, lægemidler, der anvendes til at forebygge og 
behandle blodpropper </p>
</li>
<li>
<p>salmeterol, et lægemiddel, der anvendes til at behandle astma  </p>
</li>
<li>
<p>atorvastatin, fluvastatin, pitavastin, pravastatin og rosuvastatin, lægemidler, der anvendes 
til at sænke kolesterol </p>
</li>
<li>
<p>sildenafil og vardenafil, lægemidler, der anvendes til at behandle impotens og tadalafil, et 
lægemiddel, der anvendes til at behandle impotens og pulmonal hypertension </p>
</li>
<li>
<p>trazodon, et lægemiddel, der anvendes til at behandle depression </p>
</li>
<li>
<p>ciclosporin, sirolimus og tacrolimus, lægemidler, der anvendes til at kontrollere kroppens 
immunrespons efter en transplantation </p>
</li>
<li>
<p>buspiron, clorazepat, diazepam, estazolam, flurazepam, perphenazin, risperidon, 
thioridazin, zolpidem, lægemidler, der anvendes til at behandle lidelser i nervesystemet </p>
</li>
<li>
<p>colchicin, et lægemiddel, der anvendes til behandling af podagra. </p>
</li>
<li>
<p>clopidogrel, et lægemiddel, der anvendes til at nedsætte risikoen for blodpropper. </p>
</li>
</ul>
<p> Fortæl lægen, hvis De tager nogle af disse lægemidler. </p>
<p> Fortæl lægen, hvis De tager disse eller andre lægemidler. Afbryd ikke behandlingen uden først 
at kontakte Deres læge. </p>
<p>Graviditet og amning </p>
<p>Hvis De er gravid eller ammer, har mistanke om, at De er gravid, eller planlægger at blive gravid, skal 
De spørge Deres læge eller apotekspersonalet til råds, før De bruger dette lægemiddel. </p>
<ul>
<li>Fortæl det straks til lægen, hvis De er gravid, har mistanke om, at De er gravid, eller 
planlægger at blive gravid. Gravide kvinder bør ikke tage Tybost sammen med atazanavir </li>
</ul>
<p>eller darunavir. Mængden af disse lægemidler i Deres blod kan falde under graviditet, hvilket 
kan forhindre dem i at virke korrekt.  </p>
<ul>
<li>
<p>De må ikke amme, mens De er i behandling med Tybost. Det er ukendt, om det aktive stof i 
dette lægemiddel kan udskilles i mælken hos mennesker. </p>
</li>
<li>
<p>Amning anbefales ikke hos kvinder, der er hiv-positive, da hiv-infektion kan overføres til barnet 
gennem modermælken. </p>
</li>
<li>
<p>Hvis De ammer eller påtænker at amme, bør De drøfte det med lægen hurtigst muligt. </p>
</li>
</ul>
<p>Trafik- og arbejdssikkerhed </p>
<p>Nogle patienter har indberettet svimmelhed under behandling med Tybost samtidig med atazanavir 
eller darunavir. Hvis De oplever dette, mens De tager Tybost, må De ikke føre motorkøretøj eller 
betjene værktøjer eller maskiner. </p>
<p>Tybost indeholder sunset yellow FCF (E110) </p>
<p>Fortæl lægen, hvis De er overfølsom over for sunset yellow FCF (E110). Tybost indeholder sunset 
yellow FCF, som kan forårsage allergiske reaktioner. </p>
<p>Tybost indeholder natrium </p>
<p>Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. tablet, dvs. det er i det 
væsentlige natriumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take tybost"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take tybost"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er De i tvivl, så spørg lægen eller 
apotekspersonalet. </p>
<p>Den anbefalede dosis for voksne er: </p>
<ul>
<li>
<p>En tablet om dagen gennem munden sammen med mad. Tabletten må ikke tygges, knuses 
eller deles.  </p>
</li>
<li>
<p>Tybost må ikke tages sammen med atazanavir (300 mg) eller darunavir (800 mg). </p>
</li>
</ul>
<p>Anbefalet dosis for unge i alderen 12 til under 18 år: </p>
<ul>
<li>
<p>En tablet hver dag indtaget gennem munden, sammen med mad. Tabletten må ikke tygges, 
knuses eller deles. </p>
</li>
<li>
<p>Når Tybost tages sammen med atazanavir (300 mg), skal unge veje mindst 35 kg. </p>
</li>
<li>
<p>Når Tybost tages sammen med darunavir (800 mg), skal unge veje mindst 40 kg. </p>
</li>
</ul>
<p>Tag altid den dosis, Deres læge har anbefalet for at sikre, at medicinen er fuldt ud effektiv. De må 
ikke ændre Deres dosis, medmindre De har fået besked på det af Deres læge. </p>
<p>Hvis De har taget for meget Tybost </p>
<p>Hvis De ved et uheld tager mere end den anbefalede dosis Tybost, kan De have større risiko for at få 
bivirkninger med denne medicin (se punkt 4 i denne indlægsseddel). </p>
<p>Kontakt straks lægen eller den nærmeste skadestue for at få råd. Tag tabletbeholderen med, så De let 
kan vise, hvad De har taget. </p>
<p>Hvis De har glemt at tage Tybost </p>
<p>Det er vigtigt, at De husker at tage hver dosis af Tybost. </p>
<p>Hvis De har glemt at tage en dosis og kommer i tanker om det: </p>
<ul>
<li>
<p>inden 12 timer efter det tidspunkt, De normalt tager Tybost på, skal De tage tabletten så hurtigt 
som muligt. Tag altid tabletten sammen med mad. Derefter tages den næste dosis som 
sædvanligt i kombination med atazanavir eller darunavir. </p>
</li>
<li>
<p>12 timer eller længere efter det tidspunkt, De normalt tager Tybost på, skal De ikke tage den 
glemte dosis. Vent og tag den næste dosis sammen med mad, til sædvanlig tid. </p>
</li>
</ul>
<p>Hold ikke op med at tage Tybost </p>
<p>Hold ikke op med at tage Tybost uden at tale med Deres læge. Hvis De holder op med at tage 
Tybost samt atazanavir eller darunavir, kan det nedsætte, hvor vellykkede fremtidige behandlinger, 
ordineret af Deres læge, bliver. </p>
<p>Opbevar altid nok Tybost, så du ikke løber tør. Når De snart ikke har mere af Tybost, skal De bede 
om mere fra lægen eller på apoteket. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, De er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. Når 
hiv-infektion behandles, er det ikke altid muligt at afgøre, om nogle af de uønskede virkninger er 
forårsaget af Tybost eller af anden medicin, som De tager samtidigt, eller af selve hiv-sygdommen. 
Der kan opstå følgende bivirkninger, når De tager Tybost sammen med atazanavir. </p>
<p>Meget almindelige bivirkninger 
(kan opstå hos flere end 1 ud af 10 personer) </p>
<ul>
<li>
<p>kvalme </p>
</li>
<li>
<p>gulfarvning af hud og/eller øjne (gulsot) 
Almindelige bivirkninger 
(kan opstå hos op til 1 ud af 10 personer) </p>
</li>
<li>
<p>høje sukkerniveauer i blodet (hyperglykæmi) </p>
</li>
<li>
<p>øget appetit, smagsforstyrrelse, tør mund </p>
</li>
<li>
<p>hovedpine, svimmelhed </p>
</li>
<li>
<p>opkastning, diarré, mavesmerter, fordøjelsesproblemer, som resulterer i smerter efter måltider 
(dyspepsi), oppustethed, afgang af tarmluft (flatulens) </p>
</li>
<li>
<p>øgede niveauer af bilirubin i blodet (hyperbilirubinæmi) </p>
</li>
<li>
<p>udslæt </p>
</li>
<li>
<p>søvnbesvær, unormale drømme, døsighed, træthed 
Ikke almindelige bivirkninger 
(kan opstå hos op til 1 ud af 100 personer) </p>
</li>
<li>
<p>blod i urinen (hæmaturi) </p>
</li>
<li>
<p>protein i urinen (proteinuri) </p>
</li>
<li>
<p>følelse af nedtrykthed </p>
</li>
<li>
<p>kløe </p>
</li>
<li>
<p>ømme muskler, svaghed </p>
</li>
<li>
<p>nyresten </p>
</li>
<li>
<p>feber </p>
</li>
<li>
<p>søvnforstyrrelse </p>
</li>
</ul>
<p>Indberetning af bivirkninger 
Hvis De oplever bivirkninger, bør De tale med Deres læge eller apotekspersonalet. Dette gælder 
også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. De eller Deres pårørende 
kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan De hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>
<p>For yderligere oplysninger om bivirkninger ved atazanavir eller darunavir, se disse lægemidlers 
indlægssedler. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store tybost"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store tybost"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på pakningen efter (EXP). Udløbsdatoen er den 
sidste dag i den nævnte måned.  </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen. </p>
<p>Spørg apotekspersonalet, hvordan De skal bortskaffe lægemiddelrester. Af hensyn til miljøet må De 
ikke smide lægemiddelrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tybost indeholder: </p>
<p>Aktivt stof: cobicistat. Hver filmovertrukken tablet indeholder 150 mg cobicistat. </p>
<p>Øvrige indholdsstoffer: </p>
<p>Tabletkerne 
Croscarmellosenatrium, magnesiumstearat, mikrokrystallinsk cellulose (E460), siliciumdioxid (E551). </p>
<p>Filmovertræk 
Sunset yellow FCF (E110), macrogol 3350 (E1521), polyvinylalkohol (delvist hydrolyseret) (E1203), 
talkum (E553b), titandioxid (E171), gul jernoxid (E172) (se punkt 2 i denne indlægsseddel). </p>
<p>Udseende og pakningsstørrelser </p>
<p>Tybost filmovertrukne tabletter er orange, runde, bikonvekse tabletter, som er præget med "GSI" på 
den ene side og glatte på den anden side af tabletten. </p>
<p>Tybost leveres i tabletbeholdere, der indeholder 30 tabletter (med et brev eller en beholder med 
silicagel, der skal opbevares i beholderen for at hjælpe med at beskytte tabletterne). Silicagel-
tørremidlet er i et separat brev eller en separat beholder, og må ikke sluges. </p>
<p>Fås i pakninger, der indeholder 1 tabletbeholder med 30 filmovertrukne tabletter og 
90 (3 tabletbeholdere med 30) filmovertrukne tabletter. Ikke alle pakningsstørrelser er nødvendigvis 
markedsført. </p>
<p>Indehaver af markedsføringstilladelsen 
Gilead Sciences Ireland UC 
Carrigtohill 
County Cork, T45 DPIrland </p>
<p>Fremstiller 
Gilead Sciences Ireland UC 
IDA Business &amp; Technology Park 
Carrigtohill 
County Cork 
Irland </p>
<p>Hvis De ønsker yderligere oplysninger om dette lægemiddel, skal De henvende Dem til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Gilead Sciences Belgium SRL-BV 
Tél/Tel: + 32 (0) 24 01 35<br />
Lietuva 
Gilead Sciences Ireland UC 
Tel: + 353 (0) 1 686 1 
България 
Gilead Sciences Ireland UC 
Тел.: + 353 (0) 1 686 1 
Luxembourg/Luxemburg 
Gilead Sciences Belgium SPRL-BVBA 
Tél/Tel: + 32 (0) 24 01 35<br />
Česká republika 
Gilead Sciences s.r.o. 
Tel: + 420 910 871<br />
Magyarország 
Gilead Sciences Ireland UC 
Tel.: + 353 (0) 1 686 1 
Danmark 
Gilead Sciences Sweden AB 
Tlf.: + 46 (0) 8 5057 1 
Malta 
Gilead Sciences Ireland UC 
Tel: + 353 (0) 1 686 1 
Deutschland 
Gilead Sciences GmbH 
Tel: + 49 (0) 89 899890-0 </p>
<p>Nederland 
Gilead Sciences Netherlands B.V. 
Tel: + 31 (0) 20 718 36<br />
Eesti 
Gilead Sciences Ireland UC 
Tel: + 353 (0) 1 686 1 
Norge 
Gilead Sciences Sweden AB 
Tlf: + 46 (0) 8 5057 1 
Ελλάδα 
Gilead Sciences Ελλάς Μ.ΕΠΕ. 
Τηλ: + 30 210 8930<br />
Österreich 
Gilead Sciences GesmbH 
Tel: + 43 1 260<br />
España 
Gilead Sciences, S.L. 
Tel: + 34 91 378 98<br />
Polska 
Gilead Sciences Poland Sp. z o.o. 
Tel.: + 48 22 262 8 
France 
Gilead Sciences 
Tél: + 33 (0) 1 46 09 41<br />
Portugal 
Gilead Sciences, Lda. 
Tel: + 351 21 7928 
Hrvatska 
Gilead Sciences Ireland UC 
Tel: + 353 (0) 1 686 1 
România 
Gilead Sciences (GSR) S.R.L. 
Tel: + 40 31 631 18  </p>
<p>Ireland 
Gilead Sciences Ireland UC 
Tel: + 353 (0) 214 825<br />
Slovenija 
Gilead Sciences Ireland UC 
Tel: + 353 (0) 1 686 1 
Ísland 
Gilead Sciences Sweden AB 
Sími: + 46 (0) 8 5057 1 
Slovenská republika 
Gilead Sciences Slovakia s.r.o. 
Tel: + 421 232 121<br />
Italia 
Gilead Sciences S.r.l. 
Tel: + 39 02 439 
Suomi/Finland 
Gilead Sciences Sweden AB 
Puh/Tel: + 46 (0) 8 5057 1 
Κύπρος 
Gilead Sciences Ελλάς Μ.ΕΠΕ. 
Τηλ: + 30 210 8930<br />
Sverige 
Gilead Sciences Sweden AB 
Tel: + 46 (0) 8 5057 1 
Latvija 
Gilead Sciences Ireland UC 
Tel: + 353 (0) 1 686 1 
United Kingdom (Northern Ireland) 
Gilead Sciences Ireland UC 
Tel: + 44 (0) 8000 113  </p>
<p>Denne indlægsseddel blev senest ændret {MM/ÅÅÅÅ}. </p>
<p>De kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-f9f99ae69c31ce78eb86e2425f62e81a
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for tybost Package Leaflet for language en"
Description: "ePI document Bundle for tybost Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-f9f99ae69c31ce78eb86e2425f62e81a"
* entry[0].resource = composition-en-f9f99ae69c31ce78eb86e2425f62e81a

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpf9f99ae69c31ce78eb86e2425f62e81a"
* entry[=].resource = mpf9f99ae69c31ce78eb86e2425f62e81a
                            
                    
Instance: bundlepackageleaflet-da-f9f99ae69c31ce78eb86e2425f62e81a
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for tybost Package Leaflet for language da"
Description: "ePI document Bundle for tybost Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-f9f99ae69c31ce78eb86e2425f62e81a"
* entry[0].resource = composition-da-f9f99ae69c31ce78eb86e2425f62e81a

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpf9f99ae69c31ce78eb86e2425f62e81a"
* entry[=].resource = mpf9f99ae69c31ce78eb86e2425f62e81a
                            
                    



Instance: mpf9f99ae69c31ce78eb86e2425f62e81a
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product tybost"
Description: "tybost"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/13/872/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Tybost is indicated as a pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "tybost"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: f9f99ae69c31ce78eb86e2425f62e81aListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "tybost"

* status = #current
* mode = #working

* title = "List of all ePIs associated with tybost"

* subject = Reference(mp41eee0aef9958de83574342bcb523a83)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#tybost "tybost"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-f9f99ae69c31ce78eb86e2425f62e81a) // tybost en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-f9f99ae69c31ce78eb86e2425f62e81a) // tybost da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-f9f99ae69c31ce78eb86e2425f62e81a
InstanceOf: List

* insert f9f99ae69c31ce78eb86e2425f62e81aListRuleset
    